Changes in Medicaid Coverage of Hepatitis C Therapies

The high cost of Hepatitis C treatments has led 36 state Medicaid Programs to limit their treatment coverage to only those with advanced Hepatitis C. Many states are ill-equipped to predict the long-term impact of this decision.

Our researchers used a validated hepatitis C microsimulation model on the PA Medicaid population to predict the disease outcomes and costs associated with this change. The research was published in Healthcare (The Netherlands).